5 suspended. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Suspended 5 |
Follow Healthy: new trials by email Literature Review of Healthy trials Research Report on Healthy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection. A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection), B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg), C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) - Healthy | Phase 1 | Suspended | University of Oxford | 37 | 2026-12-01 | 2025-12-26 |
| A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women BI 3031185, Midazolam, Placebo - Healthy | Phase 1 | Suspended | Boehringer Ingelheim | 100 | 2025-04-07 | 2026-10-27 |
| Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants M5542, Placebo - Healthy | Phase 1 | Suspended | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 49 | 2024-09-12 | 2026-10-20 |
| Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. [Zr-89]Oxine-labeled leukocytes PET/MRI - Fibromyalgia, Chronic Fatigue Syndrome | Phase 1 | Suspended | University of Alabama at Birmingham | 120 | 2021-10-05 | 2026-06-02 |
| Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects AZD5099, Placebo - Healthy | Phase 1 | Suspended | AstraZeneca | 80 | 2011-05-01 | 2011-12-01 |
Fatigue Syndrome, Chronic (1) · Fibromyalgia (1) · Multiple Sclerosis (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Chronic Disease (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Disease Attributes (1) · Encephalomyelitis (1) · Immune System Diseases (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1) · Neuromuscular Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
2-(4-((3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino)-3-methoxy-1-piperidyl)-4-((2-methoxy-1-methylethyl)carbamoyl)thiazole-5-carboxylic acid (1) · Midazolam (1)
AstraZeneca (1) · Boehringer Ingelheim (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · University of Alabama at Birmingham (1) · University of Oxford (1)
Germany (2) · United States (2) · Thailand (1)
David Melnick (1) · Elizabeth Ashley, MD (1) · Jonathan McConathy, MD,PhD (1) · Mark Yen, MD (1)